CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Clindamycin Phosphate In 0.9% Sodium Chloride patents expire, and when can generic versions of Clindamycin Phosphate In 0.9% Sodium Chloride launch?
Clindamycin Phosphate In 0.9% Sodium Chloride is a drug marketed by Baxter Hlthcare Corp and is included in one NDA.
The generic ingredient in CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE is clindamycin phosphate. There are fifty-five drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the clindamycin phosphate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Clindamycin Phosphate In 0.9% Sodium Chloride
A generic version of CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE was approved as clindamycin phosphate by ALMAJECT on July 24th, 1987.
Summary for CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 30 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE at DailyMed |
Recent Clinical Trials for CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Daré Bioscience, Inc. | Phase 1 |
| Memorial Sloan Kettering Cancer Center | Phase 2 |
| Daré Bioscience, Inc. | Phase 3 |
See all CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE clinical trials
Pharmacology for CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE
| Drug Class | Lincosamide Antibacterial |
| Physiological Effect | Decreased Sebaceous Gland Activity Neuromuscular Blockade |
Anatomical Therapeutic Chemical (ATC) Classes for CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE
US Patents and Regulatory Information for CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baxter Hlthcare Corp | CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE | clindamycin phosphate | SOLUTION;INTRAVENOUS | 208083-001 | Apr 20, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Baxter Hlthcare Corp | CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE | clindamycin phosphate | SOLUTION;INTRAVENOUS | 208083-002 | Apr 20, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Baxter Hlthcare Corp | CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE | clindamycin phosphate | SOLUTION;INTRAVENOUS | 208083-003 | Apr 20, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
